4D Molecular Therapeutics, Inc.(FDMT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,344 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
FDMT Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for 4D Molecular Therapeutics, Inc. (FDMT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores FDMT at 34.5/100 on a 32-signal composite quality model, placing it at rank #2,344 of 2,961 stocks — the bottom half of the AI-ranked universe. FDMT scores in the top quartile across revenue growth (99.3), institutional flow (97.4). Areas of concern include free cash flow (5.0) and profitability (5.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), 4D Molecular Therapeutics, Inc. reports quarterly revenue of $3.8M, net income of $-72.9M. Top institutional holders of FDMT by reported 13-F value include Jupiter Topco, RA CAPITAL MANAGEMENT, L.P., BlackRock, based on the most recent SEC filings. FDMT trades on the Nasdaq exchange and files with the SEC under CIK 1650648. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FDMT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for 4D Molecular Therapeutics, Inc. directly from SEC EDGAR. 4D Molecular Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 3 and 35 since 2021, currently 34.5 — an improving long-term trajectory across 67 quarterly and live scoring snapshots.
Revenue
Q2 2026
$3.8M
Net Income
Q2 2026
$-72.9M
ROIC
Q2 2026
-72.1%
D/E Ratio
Q2 2026
0.05
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+230194.6% YoYNet Income
+12.9% YoYOperating Income
+15.1% YoYEPS (Diluted)
+18.8% YoYTotal Assets
+1.1% YoYTotal Debt
Op. Cash Flow
+18.9% YoYFree Cash Flow
+20.8% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $85.2M +230194.6% | $37.0K -99.8% | $20.7M +562.3% | $3.1M -82.7% | $18.0M +32.5% | $13.6M |
| Net Income | $-140.1M +12.9% | $-160.9M -59.5% | $-100.8M +6.2% | $-107.5M -50.7% | $-71.3M -25.8% | $-56.7M |
| Operating Income | $-159.5M +15.1% | $-187.8M -66.4% | $-112.9M -2.6% | $-110.0M -54.3% | $-71.3M -25.9% | $-56.7M |
| EPS (Diluted) | $-2.42 +18.8% | $-2.98 -15.5% | $-2.58 +22.3% | $-3.32 -29.2% | $-2.57 | — |
| Total Assets | $566.7M +1.1% | $560.4M +64.9% | $339.9M +29.8% | $261.8M -25.9% | $353.5M +22.6% | $288.3M |
| Total Debt | $0.00 | — | — | — | — | — |
| Operating Cash Flow | $-109.1M +18.9% | $-134.6M -77.6% | $-75.8M +12.6% | $-86.7M -25.4% | $-69.1M -35.8% | $-50.9M |
| Free Cash Flow | $-109.6M +20.8% | $-138.4M -76.1% | $-78.6M +20.0% | $-98.2M -25.5% | $-78.2M -50.7% | $-51.9M |
Get alerted when FDMT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for 4D Molecular Therapeutics, Inc. including:
Top Institutional Holders of FDMT
Jupiter Topco LLC
$76.5M5,746,289 shRA CAPITAL MANAGEMENT, L.P.
$67.2M5,049,779 shBlackRock, Inc.
$60.5M4,546,059 shGOLDMAN SACHS GROUP INC
$56.6M4,258,668 shNovo Holdings A/S
$43.2M3,249,178 shSTATE STREET CORP
$38.7M2,911,109 shBVF INC/IL
$38.3M2,879,289 shT. Rowe Price Investment Management, Inc.
$33.4M2,511,887 shADAGE CAPITAL PARTNERS GP, L.L.C.
$29.9M2,249,203 shTrails Edge Capital Partners, LP
$29.6M2,227,917 sh
| Fund | Value | Shares |
|---|---|---|
| Jupiter Topco LLC | $76.5M | 5,746,289 |
| RA CAPITAL MANAGEMENT, L.P. | $67.2M | 5,049,779 |
| BlackRock, Inc. | $60.5M | 4,546,059 |
| GOLDMAN SACHS GROUP INC | $56.6M | 4,258,668 |
| Novo Holdings A/S | $43.2M | 3,249,178 |
| STATE STREET CORP | $38.7M | 2,911,109 |
| BVF INC/IL | $38.3M | 2,879,289 |
| T. Rowe Price Investment Management, Inc. | $33.4M | 2,511,887 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $29.9M | 2,249,203 |
| Trails Edge Capital Partners, LP | $29.6M | 2,227,917 |
Companies Similar to FDMT
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Altimmune, Inc.
Editas Medicine, Inc.
Upstream Bio, Inc.
Orchestra BioMed Holdings, Inc.
Century Therapeutics, Inc.
Inhibrx Biosciences, Inc.
Phathom Pharmaceuticals, Inc.
Atai Beckley N.V.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put FDMT on your watchlist
Track score changes the day 4D Molecular Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is FDMT a good stock to buy?
13F Pro's AI-powered analysis of 4D Molecular Therapeutics, Inc. (FDMT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for FDMT are available on the FDMT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. FDMT is classified as a small company.
Which hedge funds own FDMT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling FDMT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of 4D Molecular Therapeutics, Inc.'s investment landscape.